SERPASIL-ESIDRIX #1
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SERPASIL-ESIDRIX #1 (SERPASIL-ESIDRIX #1).
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
| Metabolism | Reserpine: extensive hepatic metabolism; Hydrochlorothiazide: not significantly metabolized, excreted unchanged in urine. |
| Excretion | Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged). |
| Half-life | Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal). |
| Protein binding | Reserpine: 96% bound to albumin. Hydrochlorothiazide: 68% bound to plasma proteins. |
| Volume of Distribution | Reserpine: 6-8 L/kg (extensive tissue binding, especially adrenergic neurons). Hydrochlorothiazide: 0.8-1.0 L/kg (enters erythrocytes). |
| Bioavailability | Reserpine: oral 30-50% (presystemic metabolism). Hydrochlorothiazide: oral 65-75%. |
| Onset of Action | Reserpine: oral 3-6 days; IM 1-3 hours. Hydrochlorothiazide: oral 2 hours; diuresis peaks at 4-6 hours. |
| Duration of Action | Reserpine: oral 1-6 weeks (cumulative effect); antihypertensive effect persists after discontinuation. Hydrochlorothiazide: oral 6-12 hours. |
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-50 mL/min: reduce dose by 50% or extend interval. eGFR <30 mL/min: contraindicated due to thiazide ineffectiveness. |
| Liver impairment | Child-Pugh A: standard dosing. Child-Pugh B: reduce reserpine dose by 50%. Child-Pugh C: avoid use. |
| Pediatric use | Reserpine: 0.005-0.02 mg/kg/day orally in 1-2 divided doses. Hydrochlorothiazide: 1-2 mg/kg/day orally in 2 divided doses. Adjust per response. |
| Geriatric use | Start at half the standard dose (0.5 tablet orally daily). Titrate slowly due to increased sensitivity to hypotension, CNS depression, and electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SERPASIL-ESIDRIX #1 (SERPASIL-ESIDRIX #1).
| Breastfeeding | Reserpine excreted in breast milk; M/P ratio not established. Concentrations may be low but can cause infant respiratory depression, nasal congestion, and cyanosis. Hydrochlorothiazide also excreted; may suppress lactation. Contraindicated during breastfeeding. |
| Teratogenic Risk | First trimester: Reserpine crosses placenta; associated with increased risk of congenital malformations (neural tube defects, cardiovascular anomalies) based on animal data and limited human reports. Second/third trimester: Use associated with fetal bradycardia, hypotonia, hypothermia, respiratory depression, and meconium ileus due to catecholamine depletion; risk of neonatal hypotension and poor feeding. Avoid in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["History of mental depression or suicidal thoughts","Active peptic ulcer","Ulcerative colitis","Electroconvulsive therapy (ECT) within 2 weeks","Anuria","Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides"]
| Precautions | ["May cause mental depression, including suicidal risk","Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia)","Orthostatic hypotension","Increased risk of arrhythmias with digoxin","May exacerbate systemic lupus erythematosus","May activate peptic ulcer","Monitor renal function and electrolytes"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of depression. For fetus/neonate: serial ultrasound for growth restriction, amniotic fluid index, fetal heart rate monitoring; postnatal assess for bradycardia, hypotonia, respiratory distress, and electrolyte imbalances (hyponatremia, hypokalemia from thiazide). |
| Fertility Effects | Reserpine may impair fertility via suppression of hypothalamic-pituitary axis causing prolactin elevation and menstrual irregularities; hydrochlorothiazide may cause transient erectile dysfunction but no direct effect on fertility. Overall, potential for reversible reduced fertility. |